Litcius/Paper detail

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh’d Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, Eric Van Cutsem, Tao Ji, Christine Lihou, Hui‐Ling Zhen, Luis Féliz, Arndt Vogel

2020The Lancet Oncology1,577 citationsDOIOpen Access PDF

Topics & Concepts

MedicineClinical endpointFibroblast growth factor receptorInternal medicineFibroblast growth factorPhases of clinical researchCancerToxicityGastroenterologyOncologyClinical trialReceptorFibroblast Growth Factor ResearchCholangiocarcinoma and Gallbladder Cancer StudiesIgG4-Related and Inflammatory Diseases
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study | Litcius